Suppression of puerperal lactation by terguride. A double-blind study.

作者信息

Venturini P L, Horowski R, Fasce V, Valenzano M, Ferreri C, Badino G, Rainer E, Scholz A, De Cecco L

机构信息

Department of Obstetrics and Gynecology, University of Genoa, Italy.

出版信息

Gynecol Obstet Invest. 1988;26(1):33-8. doi: 10.1159/000293669.

Clinical efficacy, prolactin (PRL)-lowering effect and tolerance of terguride (an 8-alpha-ergoline derived from Lisuride which acts as a partial dopaminergic agonist) were investigated in a double-blind study on inhibition of puerperal lactation using three different daily doses of the drug (0.25, 0.5 and 1.0 mg). With 0.5 and 1.0 daily therapeutical regimens PRL levels were suppressed in a dose-dependent manner and lactation was prevented. Terguride was highly well tolerated.